Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Belgium torn over trisomy 21 and cytomegalovirus testing in pregnancy

This article was originally published in Clinica

Executive Summary

A controversy is brewing in Belgium over whether testing for trisomy 21 and cytomegalovirus should be undertaken routinely in pregnant women. Some 300 children are born handicapped as a result of trisomy 21 and cytomegalovirus every year in Belgium, and it is thought that the test would be able to detect the condition in over two thirds of cases. However, there is no uniform testing policy, although all pregnant women are tested for toxoplasmosis, HIV, hepatitis B and syphilis.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT067151

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel